Oriola

0.93 EUR

-0.53 %

7,748 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.53 %
-1.59 %
-13.25 %
-19.13 %
-16.67 %
-16.06 %
-33.09 %
-49.07 %
-49.44 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
172.35M EUR
Turnover
113.06K EUR
P/E (adj.) (26e)
16.93
EV/EBIT (adj.) (26e)
1.71
P/B (26e)
1.74
EV/S (26e)
0.18
Dividend yield-% (26e)
3.23 %
Coverage
Recommendation
Accumulate
Target price
1.10 EUR
Updated
2026-04-30
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 2026-04-30

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/7
2026

Interim report Q2'26

29/10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Solid mid-term potential - Evli

With the financial targets announced earlier along with major investments known, Oriola’s CMD was limited in terms of significant new news, which we see as a positive given earlier concerns. More clarity was however provided on the roadmap to achieving...

Oriola
Third party research

Oriola: Soft start but expecting improvement - Evli

Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year.

Oriola
Third party research

Oriola: Softer profitability, good growth - Evli

Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, with the latter up 8.1% y/y. The adj. EBITDA of EUR 7.7m fell well short of our EUR 8.5m expectations, with profitability in the Services-segment declining...

Oriola
Forum discussions
There have been changes in the ownership of the Swedish pharmacy company half-owned by Oriola. The Lithuanian owner of the other half has sold its stake in the Swedish pharmacy company from the Euroapotheca Group, which operated pharmacy activities, to another group company. Euroapotheca...
5/9/2026, 8:19 AM
by Aktivisti26
10
Quite valid points, largely the same issues I have raised regarding this myself. Coincidentally, I was just reviewing Oriola, so let’s include one image here that shows in a rather stark way how Kronans Apotek’s profitability has melted away, even though the 2022 merger should have...
5/22/2026, 7:26 AM
by Rauli_Juva
7
Rauli interviewed Oriola’s CFO Mats Danielsson Topics: 00:00 Introduction 00:13 Mats Danielsson 01:28 Key points of the updated strategy 05:48 Changes in strategy 06:38 Financial targets 07:41 Growth target 09:19 Profitability target 13:44 Investments 15:01 Associated company Kronans...
5/18/2026, 8:40 PM
by Sijoittaja-alokas
6
Let’s share this Jussi Halme video about Oriola here; the man usually talks a lot of sense. I haven’t had the chance to listen to it myself yet, but maybe it resonates with someone’s thoughts: https://www.youtube.com/watch?v=3orteSq7eXE
5/22/2026, 5:59 AM
by NukkeNukuttaja
5
Inderes Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026 - Inderes Oriola Oyj:n pörssitiedote 29.4.2026 klo 8.30Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026Ensimmäisen vuosineljänneksen tulos odotusten mukainenTammi-maaliskuun 2026 pääkohdat Laskutus... The loss includes...
4/29/2026, 7:16 AM
by Trivial
5
Here are Rauli’s pre-event comments regarding Oriola’s CMD festivities to be held on May 12th Oriola already announced its new financial targets in connection with the Q1 results, which will be further presented at the Capital Markets Day on May 12th. We would particularly seek clarity...
5/11/2026, 5:11 AM
by Sijoittaja-alokas
4
Here are Evli’s thoughts on Oriola. Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year. ACCUMULATE with a target price of EUR 1...
5/3/2026, 2:12 PM
by Sijoittaja-alokas
4
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.